Dave Johnson

Dave Johnson has a diverse work experience in the biopharmaceutical industry. Dave is currently the CEO and Founder of Solve Therapeutics, a venture-backed start-up focused on developing antibody-based oncology therapeutics. Dave also serves as a Board Member and Chairman at Lengo Therapeutics, a company specializing in precision medicines for cancer treatment, and at Aura Biosciences, which develops viral-like drug conjugates for targeted necrosis of cancer cells. Additionally, Dave is a Board Member and Chairman of Zentalis Pharmaceuticals, a company creating small molecules targeting cancer pathways. Dave also serves as a Board Member at Palleon Pharmaceuticals.

Prior to these roles, Dave was the CEO of Acerta Pharma, where they led the company through significant growth and oversaw multiple clinical trials. Dave also held positions at Calistoga Pharmaceuticals and Gloucester Pharmaceuticals, contributing to the development of innovative cancer therapies. Dave began their career as the Director of Medical Affairs at Favrille Inc. Overall, their expertise spans various areas of the biopharmaceutical industry, including drug development, clinical trials, and strategic transactions.

Dave Johnson attended Indiana University Bloomington from 1986 to 1991 and obtained a Bachelor's degree. No specific field of study was mentioned.